Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

JM Middeke, M Fang, Jan Cornelissen, B Mohr, FR Appelbaum, M Stadler, J Sanz, H Baurmann, G Bug, K Schafer-Eckart, U Hegenbart, T Bochtler, C Rollig, F Stolzel, RB Walter, G Ehninger, M Bornhauser, Bob Löwenberg, J Schetelig

Research output: Contribution to journalArticleAcademicpeer-review

50 Citations (Scopus)


Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl (17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.
Original languageUndefined/Unknown
Pages (from-to)2960-2967
Number of pages8
Issue number19
Publication statusPublished - 2014

Cite this